BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25881546)

  • 1. Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer.
    Meng MB; Wang HH; Zaorsky NG; Zhao XZ; Wu ZQ; Jiang B; Song YC; Zhuang HQ; Li FT; Zhao LJ; Wang CL; Li K; Wang P; Yuan ZY
    Oncotarget; 2015 Jun; 6(17):15690-703. PubMed ID: 25881546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes.
    Wang HH; Zaorsky NG; Meng MB; Zeng XL; Deng L; Song YC; Zhuang HQ; Li FT; Zhao LJ; Yuan ZY; Wang P; Hao XS
    Oncotarget; 2016 Apr; 7(14):18135-45. PubMed ID: 26919113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
    Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
    Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results.
    Manabe Y; Shibamoto Y; Baba F; Yanagi T; Iwata H; Miyakawa A; Murai T; Okuda K
    Jpn J Radiol; 2018 Dec; 36(12):719-725. PubMed ID: 30218253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
    Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.
    Kelley KD; Benninghoff DL; Stein JS; Li JZ; Byrnes RT; Potters L; Knisely JP; Zinkin HD
    Radiat Oncol; 2015 May; 10():120. PubMed ID: 26018408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Horne ZD; Richman AH; Dohopolski MJ; Clump DA; Burton SA; Heron DE
    Lung Cancer; 2018 Jan; 115():1-4. PubMed ID: 29290248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
    Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control.
    Iorio-Morin C; Masson-Côté L; Ezahr Y; Blanchard J; Ebacher A; Mathieu D
    J Neurosurg; 2014 Dec; 121 Suppl():69-74. PubMed ID: 25434939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors.
    Verma V; Shostrom VK; Kumar SS; Zhen W; Hallemeier CL; Braunstein SE; Holland J; Harkenrider MM; S Iskhanian A; Neboori HJ; Jabbour SK; Attia A; Lee P; Alite F; Walker JM; Stahl JM; Wang K; Bingham BS; Hadzitheodorou C; Decker RH; McGarry RC; Simone CB
    Cancer; 2017 Feb; 123(4):688-696. PubMed ID: 27741355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups.
    Macchia G; Lazzari R; Colombo N; Laliscia C; Capelli G; D'Agostino GR; Deodato F; Maranzano E; Ippolito E; Ronchi S; Paiar F; Scorsetti M; Cilla S; Ingargiola R; Huscher A; Cerrotta AM; Fodor A; Vicenzi L; Russo D; Borghesi S; Perrucci E; Pignata S; Aristei C; Morganti AG; Scambia G; Valentini V; Jereczek-Fossa BA; Ferrandina G
    Oncologist; 2020 Feb; 25(2):e311-e320. PubMed ID: 32043791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
    Wang Z; Zhu XX; Wu XH; Li B; Shen TZ; Kong QT; Li J; Liu ZB; Jiang WR; Wang Y; Hou B
    Am J Clin Oncol; 2014 Apr; 37(2):148-53. PubMed ID: 23211223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.
    Kilburn JM; Lester SC; Lucas JT; Soike MH; Blackstock AW; Kearns WT; Hinson WH; Miller AA; Petty WJ; Munley MT; Urbanic JJ
    J Thorac Oncol; 2014 Apr; 9(4):572-6. PubMed ID: 24736084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.
    Allibhai Z; Taremi M; Bezjak A; Brade A; Hope AJ; Sun A; Cho BC
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1064-70. PubMed ID: 24210082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
    Ost P; Jereczek-Fossa BA; Van As N; Zilli T; Tree A; Henderson D; Orecchia R; Casamassima F; Surgo A; Miralbell R; De Meerleer G
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e115-20. PubMed ID: 27133946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
    Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
    Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.